June 16, 2008 - Cardinal Health will now manufacture, compound and distribute Positron Emission Tomography (PET) radiopharmaceuticals for clinical trials, the company said today at SNM 2008.
The company will now offer its PET manufacturing and distribution services to support clinical trials of new and novel PET agents. Cardinal Health will also work with pharmaceutical companies and physicians interested in using PET products to determine the efficacy of therapeutic medications. The company owns and operates a network of over 150 nuclear pharmacies and operates 25 cyclotron-based PET radiopharmaceutical manufacturing facilities. These facilities are registered with the Food and Drug Administration (FDA) to manufacture PET radiopharmaceuticals that are used by physicians to diagnose various medical conditions.
As part of its comprehensive service, Cardinal Health will also submit drug master files to the FDA for several of the PET agents it manufactures. These files contain detailed information about the manufacturing and storing of a specific drug and can help expand the use of PET products because they allow physicians and others in the pharmaceutical industry to test PET agents in the treatment or diagnosis of disease without needing to re-file drug manufacturing information with the FDA.
For more information: www.cardinalhealth.com
April 23, 2024 
